Hospitalization and definitive radiotherapy in lung cancer: incidence, risk factors and survival impact.


Journal

BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800

Informations de publication

Date de publication:
19 Apr 2020
Historique:
received: 07 01 2020
accepted: 07 04 2020
entrez: 21 4 2020
pubmed: 21 4 2020
medline: 13 1 2021
Statut: epublish

Résumé

Unplanned hospitalization during cancer treatment is costly, can disrupt treatment, and affect patient quality of life. However, incidence and risks factors for hospitalization during lung cancer radiotherapy are not well characterized. Patients treated with definitive intent radiation (≥45 Gy) for lung cancer between 2008 and 2018 at a tertiary academic institution were identified. In addition to patient, tumor, and treatment related characteristics, specific baseline frailty markers (Charlson comorbidity index, ECOG, patient reported weight loss, BMI, hemoglobin, creatinine, albumin) were recorded. All cancer-related hospitalizations during or within 30 days of completing radiation were identified. Associations between baseline variables and any hospitalization, number of hospitalizations, and overall survival were identified using multivariable linear regression and multivariable Cox proportional-hazards models, respectively. Of 270 patients included: median age was 66.6 years (31-88), 50.4% of patients were male (n = 136), 62% were Caucasian (n = 168). Cancer-related hospitalization incidence was 17% (n = 47), of which 21% of patients hospitalized (n = 10/47) had > 1 hospitalization. On multivariable analysis, each 1 g/dL baseline drop in albumin was associated with a 2.4 times higher risk of any hospitalization (95% confidence interval (CI) 1.2-5.0, P = 0.01), and baseline hemoglobin ≤10 was associated with, on average, 2.7 more hospitalizations than having pre-treatment hemoglobin > 10 (95% CI 1.3-5.4, P = 0.01). After controlling for baseline variables, cancer-related hospitalization was associated with 1.8 times increased risk of all-cause death (95% CI: 1.02-3.1, P = 0.04). Our data show baseline factors can predict those who may be at increased risk for hospitalization, which was independently associated with increased mortality. Taken together, these data support the need for developing further studies aimed at early and aggressive interventions to decrease hospitalizations during treatment.

Sections du résumé

BACKGROUND BACKGROUND
Unplanned hospitalization during cancer treatment is costly, can disrupt treatment, and affect patient quality of life. However, incidence and risks factors for hospitalization during lung cancer radiotherapy are not well characterized.
METHODS METHODS
Patients treated with definitive intent radiation (≥45 Gy) for lung cancer between 2008 and 2018 at a tertiary academic institution were identified. In addition to patient, tumor, and treatment related characteristics, specific baseline frailty markers (Charlson comorbidity index, ECOG, patient reported weight loss, BMI, hemoglobin, creatinine, albumin) were recorded. All cancer-related hospitalizations during or within 30 days of completing radiation were identified. Associations between baseline variables and any hospitalization, number of hospitalizations, and overall survival were identified using multivariable linear regression and multivariable Cox proportional-hazards models, respectively.
RESULTS RESULTS
Of 270 patients included: median age was 66.6 years (31-88), 50.4% of patients were male (n = 136), 62% were Caucasian (n = 168). Cancer-related hospitalization incidence was 17% (n = 47), of which 21% of patients hospitalized (n = 10/47) had > 1 hospitalization. On multivariable analysis, each 1 g/dL baseline drop in albumin was associated with a 2.4 times higher risk of any hospitalization (95% confidence interval (CI) 1.2-5.0, P = 0.01), and baseline hemoglobin ≤10 was associated with, on average, 2.7 more hospitalizations than having pre-treatment hemoglobin > 10 (95% CI 1.3-5.4, P = 0.01). After controlling for baseline variables, cancer-related hospitalization was associated with 1.8 times increased risk of all-cause death (95% CI: 1.02-3.1, P = 0.04).
CONCLUSIONS CONCLUSIONS
Our data show baseline factors can predict those who may be at increased risk for hospitalization, which was independently associated with increased mortality. Taken together, these data support the need for developing further studies aimed at early and aggressive interventions to decrease hospitalizations during treatment.

Identifiants

pubmed: 32306924
doi: 10.1186/s12885-020-06843-z
pii: 10.1186/s12885-020-06843-z
pmc: PMC7169027
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

334

Références

Pract Radiat Oncol. 2015 May-Jun;5(3):e245-53
pubmed: 25413398
Oncol Nurs Forum. 2017 Sep 1;44(5):E203-E212
pubmed: 28820513
J Clin Oncol. 2005 Oct 1;23(28):6865-72
pubmed: 16192578
J Natl Cancer Inst. 1994 Mar 16;86(6):441-6
pubmed: 7907149
Lancet. 2009 Aug 1;374(9687):379-86
pubmed: 19632716
Biomed Res Int. 2018 Oct 17;2018:6804938
pubmed: 30417013
N Engl J Med. 2018 Dec 13;379(24):2342-2350
pubmed: 30280658
Cancer. 2016 Dec 15;122(24):3865-3872
pubmed: 27529755
JAMA. 1998 Apr 15;279(15):1187-93
pubmed: 9555758
Radiat Oncol J. 2015 Dec;33(4):284-93
pubmed: 26756028
Nutr J. 2010 Dec 22;9:69
pubmed: 21176210
JAMA Oncol. 2015 Dec;1(9):1333-9
pubmed: 26378774
J Clin Oncol. 2002 Jan 15;20(2):494-502
pubmed: 11786579
J Geriatr Oncol. 2013 Oct;4(4):334-9
pubmed: 24472476
Health Aff (Millwood). 2014 Oct;33(10):1793-800
pubmed: 25288424
J Geriatr Oncol. 2013 Jan;4(1):64-70
pubmed: 23525607
Mol Clin Oncol. 2018 Jul;9(1):44-49
pubmed: 29896399
Chemotherapy. 2013;59(1):42-50
pubmed: 23838903
Cancer. 2003 Aug 15;98(4):779-88
pubmed: 12910523
J Clin Oncol. 2011 Sep 1;29(25):3457-65
pubmed: 21810685
N Engl J Med. 2009 Apr 2;360(14):1418-28
pubmed: 19339721
BMC Geriatr. 2008 Sep 30;8:24
pubmed: 18826625
Lung Cancer. 2013 Dec;82(3):469-76
pubmed: 24396885

Auteurs

Sarah Z Hazell (SZ)

Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, 300 Mason Lord Drive, Baltimore, MD, 21224, USA.

Nicholas Mai (N)

Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, 300 Mason Lord Drive, Baltimore, MD, 21224, USA.

Wei Fu (W)

Department of Oncology, Biostatistics, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Chen Hu (C)

Department of Oncology, Biostatistics, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Cole Friedes (C)

Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, 300 Mason Lord Drive, Baltimore, MD, 21224, USA.

Alex Negron (A)

Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, 300 Mason Lord Drive, Baltimore, MD, 21224, USA.

Khinh Ranh Voong (KR)

Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, 300 Mason Lord Drive, Baltimore, MD, 21224, USA.

Josephine L Feliciano (JL)

Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Peijin Han (P)

Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, 300 Mason Lord Drive, Baltimore, MD, 21224, USA.

Samantha Myers (S)

Department of Oncology, Johns Hopkins University School of Medicine, Baltimore, MD, USA.

Todd R McNutt (TR)

Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, 300 Mason Lord Drive, Baltimore, MD, 21224, USA.

Russell K Hales (RK)

Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, 300 Mason Lord Drive, Baltimore, MD, 21224, USA. rhales1@jhmi.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH